The short answer
MOTS-c has no identified receptor, an unresolved question about where it is translated, a mechanism described as indirect, and two oxidation-prone residues. Each of these is a structural obstacle to producing the kind of evidence the field would want.
Key facts
- Receptor
- None identified
- Site of translation
- Not settled
- Mechanism
- Indirect, via folate cycle and AMPK
- Chemistry
- Two oxidation-prone methionines
- Human data
- Correlational
- Interventional trials
- None established
No receptor means no standard toolkit
A defined receptor gives a field its instruments: binding assays, dose-response curves, selective antagonists to prove that an observed effect runs through the proposed pathway. Without one, an effect can be measured but not readily attributed. This is the same gap that has kept DSIP unresolved for nearly fifty years, and it is the single most limiting feature here.
The translation question is upstream of everything
Mitochondrial and nuclear genetic codes differ, so the same reading frame produces different peptides depending on which ribosomes read it. For a mitochondrially encoded peptide, that is not a detail. It determines what the endogenous molecule actually is. A synthetic peptide made to one interpretation may not match what a cell produces.
Research material referenced
MOTS-C 10mg, third-party HPLC tested
An indirect mechanism is harder to test
The described route runs through the folate cycle to an intermediate that activates AMPK, rather than through direct receptor engagement. Indirect mechanisms are scientifically interesting and experimentally awkward, because every step between the compound and the readout is somewhere the causal chain can break or be confounded.
The chemistry adds a practical layer
Two methionines at 12.5% of the sequence oxidise readily, producing +16 and +32 Da species. A preparation that has partly oxidised is not the compound specified, and if oxidation state is not checked it becomes an uncontrolled variable across experiments. That is a mundane obstacle and it is a real one.
Why the human evidence stays correlational
Measuring circulating levels and relating them to exercise or metabolic state produces associations. Turning those into causal claims requires intervention, and no established human interventional programme exists. The ceiling on the human data is a consequence of what has been done, not of what could be.
What would move it forward
An identified receptor or binding partner. Resolution of where translation occurs. Controlled human intervention. None of these is impossible and none has happened, and being clear about that is more useful than the promising framing that surrounds this compound. Material supplied here is for laboratory research only.
Frequently asked questions
Does MOTS-c have a known receptor?
No. Without one, effects can be measured but are difficult to attribute to a specific pathway.
Why does the site of translation matter?
Mitochondrial and nuclear genetic codes differ, so the same reading frame yields different peptides depending on which ribosomes read it.
Is there human interventional data?
No established programme. Human observations are correlational. Measured levels related to exercise or metabolic state.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedZheng Y et al., MOTS-c: a promising mitochondrial-derived peptide for therapeutic exploitation. Front Endocrinol 2023 (PMID 36761202)pubmed.ncbi.nlm.nih.gov
- PubMedMerry TL et al., Mitochondrial-derived peptides in energy metabolism. Am J Physiol Endocrinol Metab 2020 (PMID 32776825)pubmed.ncbi.nlm.nih.gov
- PubMedBender A et al. PNAS 2008 (PMID 18946048)pubmed.ncbi.nlm.nih.gov
- PubMedLee C et al. Cell Metab 2015 (PMID 25738459)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More MOTS-c (Mitochondrial Peptide) articles
- What Is MOTS-c? The Mitochondria-Encoded PeptideMOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial 12S rRNA gene. Discovery, AMPK mechanism, nuclear signalling and the published literature.
- What Is a Mitochondrial-Derived Peptide?Humanin, MOTS-c and the SHLPs are encoded in mitochondrial DNA rather than the nucleus. Why that matters, and how they were found hiding inside rRNA genes.
- MOTS-c Structure, Sequence and Physical PropertiesMOTS-c is H-MRWQEMGYIFYPRKLR-OH, 16 residues, 2,174.6 Da, formula C101H152N28O22S2. Sequence features, charge, and why the methionines matter for handling.
- MOTS-c Mechanism: AMPK Activation via the Folate CycleMOTS-c activates AMPK indirectly, by inhibiting the folate cycle and de novo purine synthesis so AICAR accumulates. Why that differs from metformin and AMP.
- MOTS-c Nuclear Translocation Under Metabolic StressIn 2018 MOTS-c was shown to move into the nucleus under metabolic stress and regulate antioxidant response element genes - retrograde signalling from mtDNA.